Key Points
- GIC Private Ltd. sold 271,994 Medline shares at an average price of $35.33, generating approximately $9.6 million and reducing its position by 1.08%. The shareholder also sold nearly 2 million shares the previous day.
- Medline reported quarterly EPS of $0.50, beating the $0.32 consensus estimate, on approximately $7.68 billion in revenue. The company raised its 2026 organic-sales-growth outlook to 9%–10% but lowered adjusted EBITDA guidance to $3.3 billion–$3.4 billion.
- Analysts remain broadly positive, with a “Moderate Buy” consensus and an average price target of $48.50, although shareholder selling and reported legal investigations related to alleged FDA violations add potential investor and regulatory risks.
Medline (NASDAQ:MDLN - Get Free Report) major shareholder Private Ltd Gic sold 271,994 shares of Medline stock in a transaction that occurred on Thursday, August 6th. The stock was sold at an average price of $35.33, for a total transaction of $9,609,548.02. Following the transaction, the insider directly owned 24,992,766 shares in the company, valued at $882,994,422.78. The trade was a 1.08% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Large shareholders that own more than 10% of a company's stock are required to disclose their transactions with the SEC.
Private Ltd Gic also recently made the following trade(s):
- On Wednesday, August 5th, Private Ltd Gic sold 1,976,618 shares of Medline stock. The shares were sold at an average price of $35.60, for a total transaction of $70,367,600.80.
Medline Trading Up 2.1%
MDLN opened at $35.23 on Friday. The firm's fifty day moving average is $38.22 and its two-hundred day moving average is $41.72. The firm has a market cap of $46.28 billion and a PE ratio of 110.09. Medline has a twelve month low of $32.81 and a twelve month high of $50.88. The company has a debt-to-equity ratio of 0.66, a quick ratio of 2.51 and a current ratio of 4.33.
Medline (NASDAQ:MDLN - Get Free Report) last issued its quarterly earnings data on Wednesday, August 5th. The company reported $0.50 EPS for the quarter, topping the consensus estimate of $0.32 by $0.18. The business had revenue of $7.68 billion for the quarter. Equities research analysts anticipate that Medline will post 1.49 EPS for the current year.
More Medline News
Here are the key news stories impacting Medline this week:
- Positive Sentiment: Medline reported second-quarter earnings of $0.50 per share, well above the $0.32 analyst consensus, on $7.69 billion in revenue. The company also raised its 2026 organic-sales-growth outlook to 9%–10%, signaling continued demand for its medical-supply products. Medline Q2 Earnings Snapshot Medline raises 2026 organic sales outlook
- Positive Sentiment: Analysts remain constructive: BTIG reiterated a Buy rating with a $55 price target, while Truist and Stifel maintained Buy ratings with targets of $47 and $45, respectively. Although both firms reduced their targets, they still imply substantial upside from recent levels. BTIG Medline rating
- Neutral Sentiment: The positive sales outlook was accompanied by a reduction in projected 2026 adjusted EBITDA to $3.3 billion–$3.4 billion. This suggests strong revenue momentum but near-term margin or cost pressures that could limit earnings growth.
- Negative Sentiment: Major shareholder GIC Private Ltd. sold approximately 2.25 million Medline shares across August 5–6 for roughly $80 million, reducing its holdings by about 8.3% overall. Large-holder selling can add supply and weigh on investor sentiment. SEC ownership filing
- Negative Sentiment: Several law firms announced investigations into potential securities-law violations following previously reported FDA violations. The announcements do not establish wrongdoing, but they introduce potential legal, regulatory, and reputational risks for Medline. Kaplan Fox Medline investigation Kessler Topaz Medline investigation
Wall Street Analyst Weigh In
Several research firms have recently weighed in on MDLN. Barclays cut their price objective on Medline from $50.00 to $45.00 and set an "overweight" rating on the stock in a report on Monday, June 1st. Evercore set a $39.00 target price on shares of Medline in a report on Thursday. Citigroup cut their price target on shares of Medline from $60.00 to $55.00 and set a "buy" rating on the stock in a research note on Thursday, May 7th. Sanford C. Bernstein reduced their price target on shares of Medline from $56.00 to $54.00 and set an "outperform" rating for the company in a report on Thursday, May 7th. Finally, BTIG Research reissued a "buy" rating and set a $55.00 price objective on shares of Medline in a research report on Friday, July 31st. One investment analyst has rated the stock with a Strong Buy rating, twenty-two have issued a Buy rating, five have given a Hold rating and one has assigned a Sell rating to the company's stock. According to MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average target price of $48.50.
Get Our Latest Stock Analysis on Medline
Institutional Inflows and Outflows
Institutional investors have recently made changes to their positions in the stock. Bank of New York Mellon Corp bought a new stake in shares of Medline during the 2nd quarter worth approximately $40,430,000. E. Ohman J or Asset Management AB bought a new stake in Medline during the second quarter worth $508,000. GAMMA Investing LLC lifted its stake in Medline by 68.3% in the second quarter. GAMMA Investing LLC now owns 626 shares of the company's stock valued at $25,000 after acquiring an additional 254 shares during the last quarter. Parallel Advisors LLC grew its position in shares of Medline by 1,073.3% in the 1st quarter. Parallel Advisors LLC now owns 5,280 shares of the company's stock valued at $235,000 after acquiring an additional 4,830 shares during the period. Finally, CTC Alternative Strategies Ltd. acquired a new position in shares of Medline during the 1st quarter worth about $1,048,000.
Medline Company Profile
(
Get Free Report)
Medline (NASDAQ: MDLN) is a healthcare products and services company that manufactures, sources and distributes a wide range of medical supplies and equipment for healthcare providers. Its product portfolio spans clinical consumables and personal protective equipment, surgical and procedural supplies, wound care and incontinence products, diagnostic and laboratory supplies, and select durable medical equipment. Medline supports care settings that include hospitals, health systems, long-term care facilities, ambulatory clinics and home health providers.
In addition to product manufacturing and distribution, Medline provides supply‑chain and logistics services designed to help healthcare customers manage inventory, reduce costs and streamline operations.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
